Table 1 Baseline characteristics of patients

Age - median [IQR]

62 [52; 70]

65 [48; 71]

62 [52; 71]

0.302

Male (n, %)

100 (71.4)

11 (50.0)

89 (75.4)

0.015

Neurological medical history (n, %)

22 (15.7)

4 (18.1)

18 (15.3)

0.707

  Stroke/transient ischemic attack

9 (6.4)

0 (0.0)

9 (8.0)

0.354

  Partial epilepsy

2 (1.4)

0 (0.0)

2 (1.8)

1

  Mild cognitive alteration

4 (2.9)

1 (4.5)

3 (2.7)

0.499

  Migraine

5 (3.6)

1 (4.5)

4 (3.4)

0.580

  Trauma brain injury

2 (1.4)

1 (4.5)

1 (0.9)

0.291

  Aneurysm

1 (0.7)

1 (4.5)

0 (0.0)

0.157

Cardiovascular diseases—n(%)

70 (50.0)

12 (54.5)

58 (49.2)

0.642

Malignancies/hemopathies—n(%)

21 (15.0)

5 (22.7)

16 (13.6)

0.423

Immune diseases—n(%)

4 (2.9)

2 (9,1)

2 (1.7)

0.233

Diabetes—n(%)

21 (15.0)

3 (13.6)

18 (15.3)

1

Chronic liver disease—n(%)

2 (1.4)

0 (0.0)

2 (1.7)

1

Chronic renal disease—n(%)

9 (6.4)

3 (13.6)

6 (5.1)

0.300

Respiratory disease—n(%)

22 (15.7)

2 (9,1)

20 (16.9)

0.566

  Chronic obstructive pulmonary disease

2 (1.4)

0 (0.0)

2 (1.7)

1

  Asthma

5 (3.6)

1 (4.5)

4 (3.4)

1

  Obstructive sleep apnea

16 (11.4)

1 (4.5)

15 (12.7)

0.482

SAPS II—median [IQR]

49 [37; 64]

51 [34; 61]

49 [38; 63]

0.647

SOFA—median [IQR]

7 [4; 8]

6 [4; 8]

7 [5; 8]

0.486

 Lopinavir + ritonavir

46 (32.9)

5 (22.7)

41 (34.7)

0.271

 Remdesivir

11 (7.9)

0 (0.0)

11 (9.3)

0.282

 Hydroxychloroquine/azithromycine

52 (37.1)

8 (36.4)

44 (37.3)

0.934

 Tocilizumab

3 (2.1)

1 (4.5)

2 (1.7)

0.807

 Anakinra

1 (0.7)

0 (0.0)

1 (0.8)

1

 Dexamethasone

1 (0.7)

0 (0.0)

1 (0.8)

1

 None

25 (17.9)

7 (31.8)

18 (15.3)

0.130

Positive SARS-CoV-2 RT-PCR in nasopharyngeal swabs

140 (100)

22 (100)

118 (100)

1

Chest CT scan suggestive of SARS-CoV-2 infection

139 (99.3)

21 (95.5)

118 (100)

0.157